This mechanism was investigated by Chen et al., showing that Wnt5a binding to ROR1 enhanced pSTAT3 Y705 levels in chronic lymphocytic leukemia (CLL), and this event was ROR1 dependent as in cells lacking ROR1 or treated with ROR1 mAb cirmtuzumab, Wnt5a-mediated pSTAT3 was not observed [26]. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.